Testing empasiprubart with efgartigimod for myasthenia gravis
Treatments studied
Part of Brain & nervous system, Cancer, Immune system & allergy clinical trials.
This study adds a new drug called empasiprubart to the existing treatment efgartigimod for people with generalized myasthenia gravis (gMG) who have antibodies against acetylcholine receptors (AChR-Ab) and have only partially responded to efgartigimod. The goal is to see if the combination improves daily living more than efgartigimod alone.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a confirmed diagnosis of generalized myasthenia gravis (gMG).
- You must have antibodies against acetylcholine receptors (AChR-Ab positive).
- Your gMG must be class II, III, IVa, or IVb on the MGFA scale (mild to severe weakness).
- You must be currently taking efgartigimod and have had a partial response (improvement of less than 2 points on the MG-ADL scale).
- You need to have received vaccines for certain bacteria (meningitis and pneumonia) within the last 5 years, or be willing to get them at least 14 days before starting study drugs.
- You cannot have lupus, complement deficiency, or have recently used certain other complement inhibitors (like zilucoplan, eculizumab, or ravulizumab).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests multiple treatment combinations for people with myasthenia gravis (MG), a condition that causes muscle weakness. It aims to find safer and more effective options by comparing different therapies.
This trial tests whether nipocalimab works better than efgartigimod for people with generalized myasthenia gravis (gMG). If you have gMG with certain antibodies and current treatments aren't working well enough, this study may help find a better option.
This trial tests a new drug called empasiprubart for people with generalized myasthenia gravis (gMG) who have a certain antibody (AChR-Ab). It is given as a monthly IV infusion (into a vein) and aims to improve muscle weakness and daily functioning.
This study follows people with generalized myasthenia gravis (a condition causing muscle weakness) who are already starting a medicine called efgartigimod as part of their regular care. Researchers want to understand how this treatment affects your daily life and overall experience with the disease.
This trial tests whether a follow-up treatment with ublituximab (given as an infusion) can help myasthenia gravis patients who first received efgartigimod. The goal is to see if it provides lasting control of MG symptoms.
This study tests a new combination treatment for generalized myasthenia gravis. It combines two medications to help reduce muscle weakness and improve your daily life.
Hear when a new AChR-Ab Seropositive Generalized Myasthenia Gravis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.